BioSpace News Archive

The week has seen a series of significant updates from BioVie, Regeneron, Relay Therapeutics, Oxford University, Vistagen and Palatin.

BMS announced that the FDA approved Sotyktu for adults with moderate-to-severe plaque psoriasis, marking this indication’s first oral treatment innovation in nearly a decade.

Regeneron’s oncology strategy is centered around improving checkpoint inhibitor treatments with combination therapies, according to a pipeline overview presented Monday morning.

Pretzel Therapeutics launched Monday with $72.5 million in Series A financing to develop novel, mitochondria-based therapies to treat rare genetic disorders and diseases of aging.

Young oncologists arguably stand to gain the most at ESMO by having the opportunity to discuss industry news and network with the most experienced doctors and professionals in their field.

It was a busy weekend at ESMO 2022 with Merck, Astellas, Seagen, Regeneron, AstraZeneca and GRAIL all presenting data from their various cancer programs.

President Joe Biden tapped Ginkgo Bioworks veteran Renee Wegrzyn to helm the recently-established Advanced Research Projects Agency for Health (ARPA-H).

AstraZeneca presented data showing Imfinzi and Tagrisso boosted survival chances for patients in different forms of lung cancer at ESMO on Monday.

Novartis has had a busy few days, announcing plans to shutter a Sandoz plant, a $300 million infrastructure investment, and Cosentyx, Kisqali and Tislelizumab readouts.

Cellusion Inc. and Hangzhou Celregen Therapeutics Ltd., a member of Shanghai Fosun Pharmaceutical Co., Ltd.,and focus on regenerative medicine and cell therapy and incubated by New Drug Fund of Fosun Health Capital, announced an exclusive license agreement in the Greater China region for Celregen to develop, manufacture and commercialize CLS001.